Support our sponsors:

NZX 50 Index	3315.14	2.90
S&P/ASX 200	4274.20	21.80
Dow Jones Industrials	12845.10	17.10

Twitter

Facebook

RSS

Daily ShareChat: Fisher & Paykel Healthcare

By Jenny Ruth

Wednesday 5th August 2009

Text too small?

Fisher & Paykel Healthcare's medium-term prospects are impressive with new products potentially tripling or quadrupling the company's addressable markets, says Guy Hallwright at Forsyth Barr.

However, the stronger New Zealand dollar has prompted him to shade back his 2010 forecast.

He now expects a $73 million net profit in 2010, down from $79.5 million, assuming the New Zealand dollar remains about 65 US cents compared with the company's guidance assumption of 60 cents. That compares with the $62.2 million the company reported for the year ended March.

While FPH's current humidified ventilation products are aimed at between four and five million intensive care patients a year, new machines could expand its market outside intensive care to between

20 million and 25 million people.

"New products are taking FPH's technology out of the intensive care unit and into hospital wards and homes via non-invasive ventilation, oxygen therapy and humidity therapy," he says.

"The company is confident that its expansion into hospital ward and home respiratory therapy will keep revenue growth in respiratory and acute in mid-teen percentages for the next five to 10 years."

With its obstructive sleep apnea products, FPH previously had only relatively basis machines aimed at only about 35% of the market but new products launched in 2008 now address the entire market, Hallwright says.

Recommendation: accumulate.

Daily ShareChat articles report how the main experts in the market might view a certain share and we provide this commentary as a useful resource for investors. Content on this site does not in any way constitute a recommendation to buy, hold or sell any particular share. Investors should always seek professional advice before making any investment decisions.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.